Prot #2125-MEL-301: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

Project: Research project

StatusActive
Effective start/end date4/9/194/9/22

Funding

  • Medpace Clinical Research LLC (Prot #2125-MEL-301)
  • Idera Pharmaceuticals, Inc. (Prot #2125-MEL-301)